← 產業報告目錄
Antibody and Recombinant Protein CDMO Market Size, Share & Trends Analysis Report By Type (Antibody CDMO, Recombinant Protein CDMO), By Application (Pharmaceutical Company, Biotechnology Company, Generic Company), By Region, And By Segment Forecasts, 2024-2031
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-01-29頁數 170報告編號 INSIGHTACE-1cd055d36b
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
The Antibody and Recombinant Protein CDMO Market on a global scale was estimated at USD 16.2 billion in 2023 and is set to attain USD 36.1 billion by 2031, with a projected CAGR of 10.8% between 2024 and 2031.
Antibody and Recombinant Protein CDMO covers The antibody and recombinant protein CDMO (Contract Development and Manufacturing Organization) market represents a subset of the biopharmaceutical industry that is focused on the development as well as produ. Rapid advancements and evolving end-user preferences are reshaping how healthcare entities approach this space.
Growth is supported by a convergence of factors: rising awareness among end users, continuous product innovation, and the growing emphasis on efficiency and sustainability within the healthcare sector.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
From a regional perspective, mature markets in North America and Europe continue to hold considerable shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and growing investment in the sector.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Antibody and Recombinant Protein CDMO Market Snapshot
Chapter 4. Global Antibody and Recombinant Protein CDMO Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Type Estimates & Trend Analysis
5.1. by Type & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Type:
5.2.1. Antibody CDMO
5.2.2. Recombinant Protein CDMO
Chapter 6. Market Segmentation 2: by Application Estimates & Trend Analysis
6.1. by Application & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Application:
6.2.1. Pharmaceutical Company
6.2.2. Biotechnology Company
6.2.3. Generic Company
Chapter 7. Antibody and Recombinant Protein CDMO Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Antibody and Recombinant Protein CDMO Market Revenue (US$ Million) Estimates and Forecasts by Type, 2024-2031
7.1.2. North America Antibody and Recombinant Protein CDMO Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
7.1.3. North America Antibody and Recombinant Protein CDMO Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
7.2. Europe
7.2.1. Europe Antibody and Recombinant Protein CDMO Market Revenue (US$ Million) Estimates and Forecasts by Type, 2024-2031
7.2.2. Europe Antibody and Recombinant Protein CDMO Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
7.2.3. Europe Antibody and Recombinant Protein CDMO Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
7.3. Asia Pacific
7.3.1. Asia Pacific Antibody and Recombinant Protein CDMO Market Revenue (US$ Million) Estimates and Forecasts by Type, 2024-2031
7.3.2. Asia Pacific Antibody and Recombinant Protein CDMO Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
7.3.3. Asia Pacific Antibody and Recombinant Protein CDMO Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
7.4. Latin America
7.4.1. Latin America Antibody and Recombinant Protein CDMO Market Revenue (US$ Million) Estimates and Forecasts by Type, 2024-2031
7.4.2. Latin America Antibody and Recombinant Protein CDMO Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
7.4.3. Latin America Antibody and Recombinant Protein CDMO Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
7.5. Middle East & Africa
7.5.1. Middle East & Africa Antibody and Recombinant Protein CDMO Market Revenue (US$ Million) Estimates and Forecasts by Type, 2024-2031
7.5.2. Middle East & Africa Antibody and Recombinant Protein CDMO Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
7.5.3. Middle East & Africa Antibody and Recombinant Protein CDMO Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Batavia Biosciences
8.2.2. Cerbios-Pharma SA
8.2.3. Grifols
8.2.4. HALIX
8.2.5. Biovian Oy
8.2.6. Catalent
8.2.7. Goodwin Biotechnology
8.2.8. Merck
8.2.9. Hangzhou Hs-biopharma
8.2.10. Wuxibiologics
8.2.11. Bioinnobio
8.2.12. Thousand Oaks Biopharmaceuticals
8.2.13. Cerbios-Pharma SA
8.2.14. Eurogentec
8.2.15. HJB
8.2.16. Bibo Pharma
8.2.17. MabPlex International
8.2.18. Genscriptprobio
8.2.19. Vetter
8.2.20. Etinpro (Beijing) Co
8.2.21. Boehringer Ingelheim BioXcellence
8.2.22. Lonza
8.2.23. 3SBio Inc
8.2.24. Porton
8.2.25. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們